Att 5a Emory Univ IRB Approval Letter

Att 5a Emory Univ IRB Approval Letter.pdf

Understanding Barriers and Facilitators to HIV Prevention for Men who Have Sex with Men (MSM) - Pulse Study

Att 5a Emory Univ IRB Approval Letter

OMB: 0920-1111

Document [pdf]
Download: pdf | pdf
TO:

Paula Frew, PhD/MPH 
Principal Investigator
MedInfect
 
 
DATE:  March 2, 2015 
 
 
RE:
Expedited Approval
 
IRB00077517
Understanding Barriers and Facilitators to HIV prevention for Men Who Have Sex With Men
 
(MSM)
Thank you for submitting a new application for this protocol. This research is eligible for expedited
review under 45 CFR.46.110 and/or 21 CFR 56.110 because it poses minimal risk and fits the regulatory
categories F[6, 7] as set forth in the Federal Register. The Emory IRB reviewed it by expedited process on
02/19/2015 and granted approval effective from 02/19/2015 through 02/18/2016. Thereafter, continuation
of human subjects research activities requires the submission of a renewal application, which must be
reviewed and approved by the IRB prior to the expiration date noted above. Please note carefully the
following items with respect to this approval:
This study meets the criteria for permissible clinical research with children as set forth at 45 CFR
46.404/21 CFR 50.51.
Parental permission is waived.
Assent must be obtained of the child as per 45 CFR 46.408/21 CFR 50.55 and Emory's age-based
assent guidelines.
Waiver of signed documentation of consent for the telephone screener is granted.
There is an IAA in place for RSS to rely on Emory as the IRB of record.
The following documents were included in this review:
Study protocol, version date 12/16/2014
Contact Form
Interview Guide
Screener
5a. Pulse Recruiting Ads English 4.0
5b. Pulse Recruiting Ads Spanish 4.0
5c. Pulse Flyers English v4.0 
5d. Pulse Flyers Spanish v4.0
3a. Pulse Consent English 6.0, version date 02/09/2015
3b. Pulse Consent Spanish 6.0, version date 02/09/2015
Any reportable events (e.g., unanticipated problems involving risk to subjects or others, noncompliance,
breaches of confidentiality, HIPAA violations, protocol deviations) must be reported to the IRB according
to our Policies & Procedures at www.irb.emory.edu, immediately, promptly, or periodically. Be sure to
check the reporting guidance and contact us if you have questions.  Terms and conditions of sponsors, if

https://eresearch.emory.edu/Emory/Doc/0/QQ7GIJ81QCGKL957V8K7TTS13E/fromString.html[3/2/2015 2:30:11 PM]

any, also apply to reporting. 
Before implementing any change to this protocol (including but not limited to sample size, informed
consent, and study design), you must submit an amendment request and secure IRB approval.
In future correspondence about this matter, please refer to the IRB file ID, name of the Principal
Investigator, and study title. Thank you
Olga Dashevskaya, JD
Sr. Research Protocol Analyst 
This letter has been digitally signed

Cc:
 

Randall

Laura

Public Health

Emory University
1599 Clifton Road, 5th Floor - Atlanta, Georgia 30322
Tel: 404.712.0720 - Fax: 404.727.1358 - Email: [email protected] - Web: http://www.irb.emory.edu/
An equal opportunity, affirmative action university

 

https://eresearch.emory.edu/Emory/Doc/0/QQ7GIJ81QCGKL957V8K7TTS13E/fromString.html[3/2/2015 2:30:11 PM]


File Typeapplication/pdf
File Titlehttps://eresearch.emory.edu/Emory/Doc/0/QQ7GIJ81QCGKL957V8K7TTS13E/fromString.html
File Modified2015-09-09
File Created2015-03-02

© 2024 OMB.report | Privacy Policy